MDM2 negatively regulates the human telomerase RNA gene promoter

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Zhao, Jiangqin ^a   Bilsland, Alan ^b   Jackson, Katrina ^b   Keith, W Nicol ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; RNA; TELOMERASE; TRANSCRIPTION FACTOR SP1; CCAAT BINDING FACTOR; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TELOMERASE RNA;

ARTICLE; BINDING SITE; BLADDER CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; ENZYME ASSAY; GENE ACTIVATION; GENE ACTIVITY; GENE CONTROL; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; TRANSACTIVATION; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; METHODOLOGY; PLASMID; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

CCAAT-BINDING FACTOR; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; LUCIFERASES; MUTAGENESIS, SITE-DIRECTED; NUCLEAR PROTEINS; PLASMIDS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; RNA; SP1 TRANSCRIPTION FACTOR; TELOMERASE; TRANSCRIPTION, GENETIC;

EID: 13144291643     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-5-6     Document Type: Article

References (36)

1. Bachand F, Autexier C: Functional regions of human telomerase reverse transcriptase and human telomerase rna required for telomerase activity and rna-protein interactions. Mol Cell Biol 2001, 21:1888-1897.
2. Autexier C, Pruzan R, Funk WD, Greider CW: Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase rna. Embo J 1996, 15: 928-5935.
3. Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG, Keith WN: Lack of telomerase rna gene hterc expression in alternative lengthening of telomeres cells is associated with methylation of the hterc promoter. Cancer Res 2001, 61:27-32.
4. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 1997, 6: 011-2019.
5. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddie SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, et al: Hest2, the putative human telomerase catalytic subunit gene, is up- regulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
6. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fission yeast and human [in process citation]. Science 1997, 277:955-959.
7. Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, et al: Use of transcriptional regulatory sequences of telomerase (hter and htert) for selective killing of cancer cells. Mol Ther 2000, 2: 39-544.
8. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Jeffry Evans TR, Ganly I, Knox RJ, Plumb JA, Nicol Keith W: Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003, 22:370-380.
9. Gu J, Andreeff M, Roth JA, Fang B: Htert promoter induces tumor-specific bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 2002, 9:30-37.
10. Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ, Evans TR, Keith WN: Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug cb1954. Oncogene 2001, 20:7797-7803.
11. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP: The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 2001, 8: 68-578.
12. Zhao JQ, Glasspool RM, Hoare SF, Bilsland A, Szatmari I, Keith WN: Activation of telomerase rna gene promoter activity by nf-y, sp1, and the retinoblastoma protein and repression by sp3. Neoplasia 2000, 2:531-539.
13. Zhao J, Bilsland A, Hoare SF, Keith WN: Involvement of nf-y and sp1 binding sequences in basal transcription of the human telomerase rna gene. FEBS Lett 2003, 536:111-119.
14. Keith WN, Tom Vulliamy, Jiangqin Zhao, Can Erzik, Alan Bilsland, Cem Ar, Birsen Ulku, Anna Marrone, Philip J Mason, Monica Bessler, et al: A mutation in a functional sp1 binding site of the telomerase rna gene (hterc) promoter in a patient with paroxysmal nocturnal haemoglobinuria. BMC Blood Disord 2004, 4:3.
15. Johnson-Pais T, Degnin C, Thayer MJ: Prb induces sp1 activity by relieving inhibition mediated by mdm2. Proc Natl Acad Sci U S A 2001, 98:2211-2216.
16. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, Libertino JA, Summerhayes IC: Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 1995, 72:683-690.
17. Zhao JQ, Hoare SF, McFarlane R, Muir S, Parkinson EK, Black DM, Keith WN: Cloning and characterization of human and mouse telomerase rna gene promoter sequences. Oncogene 1998, 16: 345-1350.
18. Mantovani R, Li XY, Pessara U, Hooft van Huisjduijnen R, Benoist C, Mathis D: Dominant negative analogs of nf-ya. J Biol Chem 1994, 269:20340-20346.
19. Boyd KE, Wells J, Gutman J, Bartley SM, Farnham PJ: C-myc target gene specificity is determined by a post-dnabinding mechanism. Proc Natl Acad Sci U S A 1998, 95:13887-13892.
20. Lin SY, Black AR, Kostic D, Pajovic S, Hoover CN, Azizkhan JC: Cell cycle-regulated association of e2f1 and sp1 is related to their functional interaction. Mol Cell Biol 1996, 16: 668-1675.
21. Kim SJ, Onwuta US, Young Ik L, Li R, Botchan MR, Robbins PD: The retinoblastoma gene product regulates sp1-mediated transcription. Molecular & Cellular Biology 1992, 12:2455-2463.
22. Udvadia AJ, Rogers KT, Higgins PD, Murata Y, Martin KH, Humphrey PA, Horowitz JM: Sp-1 binds promoter elements regulated by the rb protein and sp-1- mediated transcription is stimulated by rb coexpression. Proc Natl Acad Sci U S A 1993, 90:3265-3269.
23. Guo CS, Degnin C, Fiddler TA, Stauffer D, Thayer MJ: Regulation of myod activity and muscle cell differentiation by mdm2, prb, and sp1. J Biol Chem 2003, 278:22615-22622.
24. Momand J, Jung D, Wilczynski S, Niland J: The mdm2 gene amplification database. Nucleic Acids Res 1998, 26: 453-3459.
25. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein mdm2. Nature 1995, 375:694-698.
26. Piette J, Neel H, Marechal V: Mdm2: Keeping p53 under control. Oncogene 1997, 15:1001-1010.
27. Gu L, Findley HW, Zhou M: Mdm2 induces nf-kappab/p65 expression transcriptionally through sp1- binding sites: A novel, p53-independent role of mdm2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 2002, 99:3367-3375.
28. Thut CJ, Goodrich JA, Tjian R: Repression of p53-mediated transcription by mdm2: A dual mechanism. Genes Dev 1997, 11: 974-1986.
29. Bennett MK, Osborne TF: Nutrient regulation of gene expression by the sterol regulatory element binding proteins: Increased recruitment of gene-specific coregulatory factors and selective hyperacetylation of histone h3 in vivo. Proc Natl Acad Sci U S A 2000, 97:6340-6344.
30. Imbriano C, Bolognese F, Gurtner A, Piaggio G, Mantovani R: Hsp-cbf is an nf-y-dependent coactivator of the heat shock promoters ccaat boxes. J Biol Chem 2001, 276:26332-26339.
31. Bellorini M, Lee DK, Dantonel JC, Zemzoumi K, Roeder RG, Tora L, Mantovani R: Ccaat binding nf-y-tbp interactions: Nf-yb and nf-yc require short domains adjacent to their histone fold motifs for association with tbp basic residues. Nucleic Acids Research 1997, 25:2174-2181.
32. Caretti G, Salsi V, Vecchi C, Imbriano C, Mantovani R: Dynamic recruitment of nf-y and hats on cell-cycle prometers. J Biol Chem 2003, 27:27.
33. Frontini M, Imbriano C, diSilvio A, Bell B, Bogni A, Romier C, Moras D, Tora L, Davidson I, Mantovani R: Nf-y recruitment of tfiid, multiple interactions with histone fold taf(ii)s. J Biol Chem 2002, 277:5841-5848.
34. Leveillard T, Wasylyk B: The mdm2 c-terminal region binds to tafii250 and is required for mdm2 regulation of the cyclin a promoter. J Biol Chem 1997, 272:30651-30661.
35. Shao Z, Ruppert S, Robbins PD: The retinoblastoma-susceptibility gene product binds directly to the human tata-binding protein-associated factor tafii250. Proc Natl Acad Sci U S A 1995, 92:3115-3119.
36. Buschmann T, Lin Y, Aithmitti N, Fuchs SY, Lu H, Resnick-Silverman L, Manfredi JJ, Ronai Z, Wu X: Stabilization and activation of p53 by the coactivator protein tafii31. J Biol Chem 2001, 276:13852-13857.